The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile

P. Wang, M.M. van Greevenbroek, F.G. Bouwman, M.C. Brouwers, C.J.H. van der Kallen, E. Smit, J. Keijer, E.C. Mariman*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Visfatin with the official gene name pre-B cell colony-enhancing factor 1 (PBEF) and the protein name nicotinamide phosphoribosyltransferase (NAMPT) is a recently discovered adipocyte-secreted protein that was shown by some to be associated with visceral fat and insulin resistance. To explore the link between PBEF/NAMPT/visfatin and lipid metabolism, we analyzed the relation of its plasma level with several parameters of adiposity, insulin resistance and the circulating blood lipid profile in a group of general population (n = 40) and a group of subjects who are genetically predisposed to insulin resistance and hyperlipidemia (n = 35). In both groups and pooled cohort, PBEF/NAMPT/visfatin lacked association with whole body adiposity, but correlated positively with HDL-cholesterol and negatively with triglycerides. The data suggested a negative correlation of the PBEF level with visceral fat and insulin resistance. But this negative correlation completely disappeared after adjustment for lipid profile. We concluded that circulating PBEF/NAMPT/visfatin level is an indicator of beneficial lipid profile in non-diabetic Caucasian subjects. The relation to lipid metabolism does not depend on visceral obesity and insulin resistance, but may be linked to its enzymatic function in NAD metabolism.
Original languageEnglish
Pages (from-to)971-976
JournalPflugers Archiv-European Journal of Physiology
Issue number6
Publication statusPublished - 1 Jan 2007

Cite this